InSightec to share new insights at FUS symposium

InSightec, world leader in MR-guided Focused Ultrasound (MRgFUS) will be on site at the Focused Ultrasound International Symposium (FUS) to share key insights gained in the past two years of using its non-invasive MRgFUS solution for treating a variety of neurosurgical, oncological and gynecological indications. 


InSightec has spent several years developing its market-leading technology, gaining landmark FDA approval for pain palliation caused by pain bone metastases in 2012, which was also recently granted a positive coverage policy from insurance provider Health Care Service Corporation.

The company also recently completed enrollment in a Phase III trial with its ExAblate® Neuro, intended to demonstrate safety and efficacy in using MRgFUS for treatment of essential tremors.

At the symposium, leading researchers from the U.S., Europe and Asia using the ExAblate® platform will be presenting ground breaking research in the treatment of Neurological Disorders, Brain Tumors, Bone metastases, Uterine Fibroids and translational technology research projects.

In addition to showcasing its solutions at the event, InSightec President and Chief Commercial Officer, Robert Sigal, will give an overview presentation during the Focused Ultrasound showcase, on Monday, October 13th at 6:00 PM, while VP of R&D Eyal Zadicario will take part in the "Envelope Treatment" session, on Monday, October 13th at 3:40 PM.

The FUS symposium is the world's leading forum for sharing the latest translational and clinical advances in image-guided focused ultrasound, all with the overall goal of providing alternative treatment options and improving the quality of life for millions of potential patients.

"It's very exciting to be back at the FUS Symposium. We've maintained a strong relationship with the Foundation over the years and given our increased focus on promoting the competitiveness of our therapy platform, this event is a key pillar for our industry," said Kobi Vortman, Ph.D, and InSightec CEO. "We've made several advancements in developing our unique technology in the last couple of year and we're proud to be able to share it here." 





The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Analyzing cell-free RNA could reliably predict preeclampsia